| David Apelian |
David Apelian is currently the Chief Executive Officer & Director at Eiger BioPharmaceuticals, Inc. He previously served as the Chief Executive Officer & Director at BlueSphere Bio, Inc. from 2019 to 2022. Prior to that, he held positions at Bristol Myers Squibb Co. as the Clinical Director-Infectious Diseases Group from 2002 to 2004, and at Schering-Plough Corp. as the Clinical Director-Hepatology Department from 1999 to 2002. From 2013 to 2017, he was the Chief Medical Officer & Executive Vice President at Achillion Pharmaceuticals, Inc. He also served as the Chief Medical Officer, SVP-Research & Development at GlobeImmune, Inc. from 2008 to 2013. Additionally, he held a position as Vice President at Wyeth Pharmaceuticals LLC. Dr. Apelian holds a doctorate degree from the University of Medicine & Dentistry of New Jersey, undergraduate and doctorate degrees from Rutgers State University of New Jersey, and an MBA degree from Quinnipiac University. |
| Richard A. Franco |
Richard A. Franco is currently working as the Vice President-Business Operations at Paste-ups Ltd. and as the Chief Regulatory Officer at Eiger BioPharmaceuticals, Inc. Previously, he worked as the Vice President-Marketing at LipoScience, Inc. and Arbor Pharmaceuticals LLC, as a Principal at GSK Plc, and as the Executive Vice President-Commercial Strategy at Sprout Pharmaceuticals, Inc. He completed his undergraduate degree at Michigan State University and earned an MBA from Kenan-Flagler Business School. |
| Christopher Kurtz |
Christopher Kurtz is currently the Chief Technical Officer at Eiger BioPharmaceuticals, Inc. He previously held positions at ALZA Corp., Nektar Therapeutics, Gilead Sciences, Inc., Hauser, Inc., Alexza Pharmaceuticals, Inc., Kaleo, Inc., AbbVie, Inc., Novo Nordisk Delivery Technologies, Inc., Powderject Pharmaceuticals, Inc., and Cidara Therapeutics, Inc. He also served in the United States Army and Navy. Kurtz received his undergraduate degree from The University of Colorado. |
| Colin Hislop |
Colin Hislop is currently the Senior VP-Clinical & Development Operations at Eiger BioPharmaceuticals, Inc. He previously worked as a Principal at Eli Lilly & Co. and as a Manager-Clinical Development at Procter & Gamble Co. He also held Vice President-Clinical Development positions at CV Therapeutics, Inc. and Peninsula Pharmaceuticals, Inc. from 2001 to 2005. From 2005 to 2016, he served as the Chief Medical Officer & Senior Vice President at Anthera Pharmaceuticals, Inc. He was also the Chief Development Officer at Versartis, Inc. in 2017. Dr. Hislop holds a doctorate from the University of London and an undergraduate degree from the University of Surrey. |
| Eldon C. Mayer |
Eldon C. Mayer is Chief Commercial Officer & Executive VP of Eiger BioPharmaceuticals, Inc.
In the past he held the position of Chief Commercial Officer & Executive VP for Rigel Pharmaceuticals, Inc., Associate Director-New Product Planning at Chiron Corp., Manager-Market Research at Schering-Plough Corp., Senior Vice President-Commercial Operations at Questcor Pharmaceuticals, Inc., Marketing Director of ALZA Corp., Marketing Director at Genentech, Inc. and Senior Director-Marketing at Connetics Corp.
He received an MBA from Syracuse University and an undergraduate degree from Fairleigh Dickinson University. |
| Ingrid C. Choong |
Ingrid C. Choong occupies the position of Senior Vice President-Clinical Development at Eiger BioPharmaceuticals, Inc.
In her past career Dr. Choong was Senior Scientist at Sunesis Pharmaceuticals, Inc. and Investor Relations Officer at Eiger BioPharmaceuticals, Inc.
Dr. Choong received an undergraduate degree from California Institute of Technology and a doctorate from the University of California, Berkeley. |
| William G. Kachioff |
William G. Kachioff currently works at The American Institute of Certified Public Accountants, as Member, The Association of Bioscience Financial Officers, as Member, and Eiger BioPharmaceuticals, Inc., as Chief Financial Officer from 2023. Mr. Kachioff also formerly worked at Cutera, Inc., as Finance Director, VIVUS, Inc., as Principal, Coulter Pharmaceuticals, Inc., as Principal, Biocept, Inc., as Chief Financial Officer & Senior Vice President from 2011 to 2015, Abbott Laboratories (Pakistan) Ltd., as Principal, Aduro BioTech, Inc., as Chief Financial & Accounting Officer, MicroIslet, Inc., as Chief Financial Officer from 2002 to 2005, Ajinomoto Althea, Inc., as Chief Financial Officer & Vice President from 2009 to 2011, Tatum LLC, as Chief Financial Officer, and Decipher Biosciences, Inc., as Chief Financial Officer from 2015 to 2017. Mr. Kachioff received his undergraduate degree from State University of New York at Buffalo. |
| Thomas John Dietz |
Thomas John Dietz is currently the Chairman & Chief Executive Officer at Waypoint Holdings LLC, Chairman at Galleon Pharmaceuticals, Inc., Independent Non-Executive Chairman at Eiger BioPharmaceuticals, Inc., Director at AgBiome INC, Lead Independent Director at Leap Therapeutics, Inc., Director at Nutcracker Therapeutics, Inc., Managing Member at Codfish Investments LLC, and Managing Member at Codpiece Properties LLC. He has previously worked as the Chief Executive Officer & Director at Pacific Growth Equities, Inc., Independent Director at Virobay, Inc., Independent Director at Eiger BioPharmaceuticals, Inc., Independent Director at Transcept Pharma, Inc., Independent Director at Paratek Pharmaceuticals, Inc., and Head-Investment Banking at Wedbush Securities, Inc. He has also held positions as a Member-Research Faculty at The University of California, San Francisco, a Trustee-West Bay Region at Sutter Health, and a Research Faculty Member at VA Medical Center (District of Columbia). Dietz holds a doctorate degree from Washington University in St. Louis and an undergraduate degree from State University of New York at Albany. |
| James A. Vollins |
James A. Vollins is currently the Secretary & Chief Compliance Officer at Eiger BioPharmaceuticals, Inc. Prior to this, he held the same position at BioDelivery Sciences International, Inc. from 2018 to 2022 and at Bio Products Laboratory Ltd. from 2014 to 2018. Vollins received his undergraduate degree from Wesleyan University and his graduate degree from Case Western Reserve University School of Law. |
| Kim Sablich |
Kim Sablich is an Independent Director at Eiger BioPharmaceuticals, Inc. She was previously a Director at AllerGenis LLC from 2018 to 2021, Vice President at GSK Plc from 2015 to 2018, Chief Commercial Officer at Myovant Sciences, Inc. from 2018 to 2020, and Chief Commercial Officer at Myovant Sciences Ltd. from 2018 to 2020. She is also currently serving as Executive VP & General Manager-North America at Jazz Pharmaceuticals Plc from 2020 to 2023. Ms. Sablich received her undergraduate degree from Denison University and her MBA from The Wharton School of the University of Pennsylvania. |
| Christine Murray |
Christine Murray is on the board of Eiger BioPharmaceuticals, Inc.
She previously held the position of Vice President-Regulatory Affairs at Achaogen, Inc., Senior Vice President-Global Regulatory Affairs at Ultragenyx Pharmaceutical, Inc., Vice President-Regulatory Affairs of Raptor Pharmaceuticals, Inc. and Vice President-Global Regulatory Affairs at Horizon Pharmaceutical LLC.
She received an undergraduate degree from The University of Liverpool and a graduate degree from Newcastle University. |
| Evan Loh |
Evan Loh is currently the Chief Executive Officer at Paratek Pharmaceuticals, Inc., an Independent Director at Eiger BioPharmaceuticals, Inc., and a Director at Adaptive Phage Therapeutics, Inc. Previously, he served as the Chairman & Chief Medical Officer at Paratek Pharmaceuticals, Inc. and Transcept Pharma, Inc. He was also the Chairman of the Antimicrobials Working Group. Additionally, Dr. Loh held positions as an Independent Director at Windtree Therapeutics, Inc. and Nivalis Therapeutics, Inc. He worked as the Vice President-Clinical Research & Development at Wyeth LLC and as the Senior VP-Worldwide Research & Development at Pfizer Inc. He also held the position of Vice President-Multiple Therapeutic Areas at Wyeth Pharmaceuticals LLC. Dr. Loh is a member of Harvard Medical School and Perelman School of Medicine. He holds a doctorate degree from Harvard Medical School and an undergraduate degree from Harvard College. |
| Jeffrey S. Glenn |
Jeffrey S. Glenn founded Eiger BioPharmaceuticals, Inc. and Eiger BioPharmaceuticals, Inc. Dr. Glenn is on the board of Eiger BioPharmaceuticals, Inc. and Member of American Society for Clinical Investigation and Associate Professor & Director-Hepatitis Center at Stanford University School of Medicine.
He previously held the position of Director at Eiger BioPharmaceuticals, Inc.
Dr. Glenn received an undergraduate degree from the University of California, Berkeley and a doctorate from The University of California, San Francisco. |
| Amit K. Sachdev |
Amit K. Sachdev is currently the Director at the Massachusetts Biotechnology Council, the Director at the Stanford Center on Longevity, the Independent Director at Eiger BioPharmaceuticals, Inc., the Director at Team IMPACT, Inc., the Director at Imagine An Answer To Kids Brain Cancer Foundation, and the Chief Patient Officer & Executive Vice President at Vertex Pharmaceuticals, Inc. Previously, he served as the Executive Vice President-Health at the Biotechnology Innovation Organization from 2005 to 2007, the Deputy Commissioner at the US Food & Drug Administration, and as Counsel at the U.S. House of Representatives from 1998 to 2002. He holds an undergraduate degree from Carnegie Mellon University and a graduate degree from Emory University School of Law. |
| Lisa Kelly-Croswell |
Lisa Kelly-Croswell is an Independent Director at Eiger BioPharmaceuticals, Inc. and holds the position of Chief Human Resources Officer & Senior VP at Boston Medical Center. She previously served as an Independent Director at Synlogic, Inc. from 2021 to 2024. Lisa also held senior leadership roles in human resources at Cigna Holding Co., Vertex Pharmaceuticals, Inc., NitroMed, Inc., and Monsanto Co. She has an undergraduate and graduate degree from the University of Illinois. |
